The post Denmark, Novo Holdings lead bid to back $350M quantum venture fund appeared on BitcoinEthereumNews.com. The Danish government has joined forces with Novo Holdings, the investment arm of Novo Nordisk’s controlling foundation, to anchor a €300 million, which is approximately $350 million, quantum technology venture fund. The financial vehicle is designed to cement Europe’s position in one of the most competitive areas of deep tech. The fund, launched by Copenhagen-based 55 North, has already secured a first close of €134 million and aims to become the world’s largest dedicated vehicle for quantum investments.  The initiative marks one of the most ambitious attempts yet by a European nation to bridge the gap between world-class research and commercial breakthroughs in quantum computing, sensing and communications. The Danish government and Novo have combined in funding tech  55 North’s target fund will invest across quantum computing, sensing, communications and enabling components. “When these technologies come to fruition, they could be transformative for some of the areas we care deeply about,” Soren Moller, managing partner for seed investments at Novo Holdings, said, reflecting the foundation’s interest in applications for life sciences and planetary health.  The move follows earlier, related investments where the foundation and the government jointly committed to an Nvidia-powered AI supercomputer last year. Earlier this summer, they agreed to co-fund a Microsoft-powered quantum computer, named Magne, which will be made available to industry and researchers. The Magne machine, to be built with Microsoft and Atom Computing and operated by a new entity, QuNorth, is expected to begin work by early 2027. Lab breakthroughs turn into investable companies Europe has long led in quantum science, and over the years, it has seen research coming out of the continent become investable technology firms; however, this progress isn’t moving at the pace observed in places like the US and China. 55 North’s founding team has already placed early bets in areas… The post Denmark, Novo Holdings lead bid to back $350M quantum venture fund appeared on BitcoinEthereumNews.com. The Danish government has joined forces with Novo Holdings, the investment arm of Novo Nordisk’s controlling foundation, to anchor a €300 million, which is approximately $350 million, quantum technology venture fund. The financial vehicle is designed to cement Europe’s position in one of the most competitive areas of deep tech. The fund, launched by Copenhagen-based 55 North, has already secured a first close of €134 million and aims to become the world’s largest dedicated vehicle for quantum investments.  The initiative marks one of the most ambitious attempts yet by a European nation to bridge the gap between world-class research and commercial breakthroughs in quantum computing, sensing and communications. The Danish government and Novo have combined in funding tech  55 North’s target fund will invest across quantum computing, sensing, communications and enabling components. “When these technologies come to fruition, they could be transformative for some of the areas we care deeply about,” Soren Moller, managing partner for seed investments at Novo Holdings, said, reflecting the foundation’s interest in applications for life sciences and planetary health.  The move follows earlier, related investments where the foundation and the government jointly committed to an Nvidia-powered AI supercomputer last year. Earlier this summer, they agreed to co-fund a Microsoft-powered quantum computer, named Magne, which will be made available to industry and researchers. The Magne machine, to be built with Microsoft and Atom Computing and operated by a new entity, QuNorth, is expected to begin work by early 2027. Lab breakthroughs turn into investable companies Europe has long led in quantum science, and over the years, it has seen research coming out of the continent become investable technology firms; however, this progress isn’t moving at the pace observed in places like the US and China. 55 North’s founding team has already placed early bets in areas…

Denmark, Novo Holdings lead bid to back $350M quantum venture fund

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The Danish government has joined forces with Novo Holdings, the investment arm of Novo Nordisk’s controlling foundation, to anchor a €300 million, which is approximately $350 million, quantum technology venture fund. The financial vehicle is designed to cement Europe’s position in one of the most competitive areas of deep tech.

The fund, launched by Copenhagen-based 55 North, has already secured a first close of €134 million and aims to become the world’s largest dedicated vehicle for quantum investments. 

The initiative marks one of the most ambitious attempts yet by a European nation to bridge the gap between world-class research and commercial breakthroughs in quantum computing, sensing and communications.

The Danish government and Novo have combined in funding tech 

55 North’s target fund will invest across quantum computing, sensing, communications and enabling components.

“When these technologies come to fruition, they could be transformative for some of the areas we care deeply about,” Soren Moller, managing partner for seed investments at Novo Holdings, said, reflecting the foundation’s interest in applications for life sciences and planetary health. 

The move follows earlier, related investments where the foundation and the government jointly committed to an Nvidia-powered AI supercomputer last year. Earlier this summer, they agreed to co-fund a Microsoft-powered quantum computer, named Magne, which will be made available to industry and researchers.

The Magne machine, to be built with Microsoft and Atom Computing and operated by a new entity, QuNorth, is expected to begin work by early 2027.

Lab breakthroughs turn into investable companies

Europe has long led in quantum science, and over the years, it has seen research coming out of the continent become investable technology firms; however, this progress isn’t moving at the pace observed in places like the US and China.

55 North’s founding team has already placed early bets in areas such as quantum hardware and cryogenics.

Novo Holdings, on the other hand, is known for its exploits in the pharmaceutical world. The foundation has pointed out that quantum-enabled simulation could materially accelerate drug discovery and complex molecular modelling. 

At the same time, Novo Nordisk has reason to invest and diversify as it faces mounting competitive pressures in the US obesity market and has announced substantial job reductions as it reorganizes under new leadership. 

Risks, geopolitics and the long game

Quantum technology is still largely experimental and real-world applications are growing. However, the time it may take to yield major returns to investors may take years, if not decades.

Denmark’s route of combining public backing with one of Europe’s most powerful foundations may be the way to go as funding deep technologies like this one are usually too risky for conventional venture capitalists.

Analysts point out that quantum investment in the US is the highest, with companies such as IBM, Google and Amazon pouring billions into the field. China, meanwhile, has committed heavily to national programs. Europe’s challenge will include securing essential supply chains on top of scaling its startups and retaining talent.

If successful, the fund could strengthen Europe’s role in quantum-enhanced pharmaceuticals, artificial intelligence, cybersecurity and climate modeling.

Don’t just read crypto news. Understand it. Subscribe to our newsletter. It’s free.

Source: https://www.cryptopolitan.com/denmark-novo-quantum-venture-fund/

Market Opportunity
CreatorBid Logo
CreatorBid Price(BID)
$0.008797
$0.008797$0.008797
-0.86%
USD
CreatorBid (BID) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09